Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

BIIB surprised the Street with news that it plans to file a BLA for aducanumab, or adu, in Q1 2020.

Biogen: A Trading Strategy

Lyft

McDonald's

Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.

Wednesday’s Vital Data: Biogen, McDonald’s and Lyft

"This was a thorough engagement, and as CEO I'm reasonably confident this will lead to market approval one day," Biogen CEO Michel Vounatsos says.

Biogen CEO 'reasonably confident' once-doomed Alzheimer's drug will be granted FDA approval

Biogen's risk-to-reward ratio may now be too compelling to pass up.

Biogen's Stock Could More Than Quadruple in Value in 5 Years

The reassessment of a failed Alzheimer's disease study looks more like an act of desperation than a clinical triumph.

Here's Why Biogen's Big Gain Won't Last Long

A drug once thought as dead could be rising from the ashes. Does Biogen's shocking news make the stock a buy now?

Is Biogen a Buy After the Biggest Biotech Bombshell in Years?

Biogen Inc  revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.

Biogen, Eisai revive plans for Alzheimer's drug, surprising market

One biotech zoomed 26% higher, while a prominent rideshare company saw a more-than-6% boost.

2 Stocks That Flew High on Tuesday

Biogen Inc  revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients suffering from the disease.

Biogen resurrects Alzheimer's drug; shares jump 27%

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q3 2019 Results - Earnings Call Transcript

Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.

Stock Market Today: Biogen’s Answer to Alzheimer’s

Biogen Inc (NASDAQ: BIIB) traded sharply higher on Tuesday on better than expected earnings and positive news about its Alzheimer's drug.

Jon Najarian Highlights Unusual Options Activity In Biogen

BIIB is up 25% on a surprise announcement.

Hold On To Biogen For Further Upside

Bristol-Myers

Celgene

Eli Lilly

Vertex Pharmaceuticals

Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.

5 Healthcare Stocks to Buy

Biotech stocks traded higher on Tuesday after Biogen said it would seek approval for its Alzheimer's drug.

Biotech stocks soar following shock Biogen drug announcement

Biogen Inc. BIIB, +26.85% did a good job buying low, as the biotechnology company's stock rally on Tuesday has boosted the value of the shares repurchased over the past six months by about $708.6 million.

Biogen's stock surge increases value of recent stock repurchased by over $700 million

This is about as "game changer" as a drug can get, at least in the early stages.

Biogen (BIIB) Up 40% on Alzheimer's Drug & More

Biogen Inc. (NASDAQ: BIIB) released its third-quarter financial results before the markets opened on Tuesday.

Why Biogen’s Alzheimer’s Study Is Overshadowing Its Big Earnings Beat

Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab.

Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab

Drug maker Biogen announced it is seeking regulatory approval for its Alzheimer's drug, months after it stopped testing the treatment.

Biogen soars 40% on hopes of Alzheimer's treatment approval, may be 'biggest drug ever,' says Cramer

Biogen Inc (NASDAQ: BIIB) shares, which suffered a severe setback in early 2019 after the company's Alzheimer's program flopped, were seeing a resurgence Tuesday.

Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis

Biogen (BIIB) Q3 Earnings & Sales Beat Estimates

Biogen stock rocketed Tuesday after Biogen earnings of $9.17 per share on $3.6 billion in sales topped estimates. Biogen also plans to ask for approval of an Alzheimer's treatment.

Biogen Stock Rockets On Plans To Seek Approval For Alzheimer's Drug

Shares of Biogen Inc. BIIB, +1.57% soared 40.5% on heavy volume toward a record gain in premarket trading Tuesday, after the biotechnology company said it will pursue FDA approval of its Alzheimer's treatment aducanumab after upbeat trial results and reported a third-quarter profit that was well above expectations.

Biogen's stock soars toward record rally, set to add nearly $17 billion to market cap

The drug had been written off as a failure after a review committee found it to be ineffective.
It’s been touted as a “game changer” and ultimately deemed a “failure,” but now it’s getting a second chance.

News for Biogen Stock (BIIB)